Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.46 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | BPTF | Q12830 | 2/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407479 | 0.98 | AURKA (0.46) | AURKAPTK6ADRA2AADRA2BADRA2C | |
| SCHEMBL408777 | 0.82 | AURKA (0.50) | AURKAPTK6 | |
| SCHEMBL408411 | 0.81 | AURKA (0.62) | AURKA | |
| SCHEMBL407996 | 0.81 | AURKA (0.58) | AURKAPTK6 | |
| SCHEMBL408059 | 0.81 | AURKA (0.49) | AURKAPTK6 | |
| SCHEMBL407482 | 0.81 | AURKA (0.44) | AURKAPTK6ADRA2AADRA2BADRA2C | |
| SCHEMBL409000 | 0.80 | AURKA (0.48) | AURKAPTK6 | |
| Hydrochloric Acid SCHEMBL403430 | 0.80 | AURKA (0.49) | AURKAPTK6 | |
| Hydrochloric Acid SCHEMBL408539 | 0.80 | AURKA (0.43) | AURKAPTK6ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL407997 | 0.79 | AURKA (0.48) | AURKAPTK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022060-A1 | Tricyclic Azaindoles | AZI2, DCK, PPP2CA | AURKA 515/4885PTK6 401/4885ADRA2A 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.